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CorrespondenceResponse: Association of Duffy
Antigen Genotypes with HIV-AIDS
SusceptibilityWe appreciate the correspondences
regarding our report on the association
of DARC 46C/C genotype with HIV-
AIDS susceptibility (He et al., 2008). First,
wewish to respond to thequestions raised
regarding our method for adjustment of
admixture, for which we had used 11
genetic markers that predicted self-re-
ported ethnicity with >98% accuracy. To
address this issue further, we examined
96 well-characterized, ancestry-informa-
tive markers (AIMs) (Kosoy et al., 2009) in
360 randomly selected European Ameri-
cans (EAs) and African Americans (AAs)
(90 HIV-positive and 90 HIV-negative for
each ethnicity) from our original study
population. These randomly selected indi-
viduals were not significantly different
from the remainder of the study subjects
with respect to DARC 46T/C genotypes
and clinical characteristics (e.g., CD4 cell
counts and steady-state viral load [VL]
among HIV-positive subjects). We also
examined population reference groups
from the HapMap (European [CEU, n =
60] and African [YRI, n = 60]). The 46T/
C polymorphism (rs2814778) was not
present in either genetic marker set.
Principal component analyses using
EIGENSOFT indicated that the first prin-
cipal component (PC1) clearly separated
subjects of European and African ancestry
(p < 0.0001). Comparison of PC1 between
the HIV-positive and HIV-negative AAs
revealed minimal population stratification
(Mann-Whitney test p = 0.43 and 0.48
with 96 and 11 markers, respectively).
Additionally, PC1 of the 96 and 11markers
were highly correlated (r = 0.85; p <
0.0001). Finally, the association of DARC
46C/C with increased risk of acquiring
HIV remained after adjusting for PC1 of
the 11 markers (OR = 1.56; 95% CI =
1.14–2.13, p = 0.005). These data sug-
gested that our original findings were not
the result of population stratification.
Similar inferences were obtained using
STRUCTURE.
The epidemiological features (e.g.,
representativeness of subject selection
and controls, sample size, route of infec-
tion, endpoints analyzed) of the four418 Cell Host & Microbe 5, May 21, 2009 ªstudies reported in these correspon-
dences may limit direct comparability
withourwork. InHeetal. (2008) andWalley
et al., the prevalence of DARC 46C/C
(70%) was similar in HIV-positive AAs,
but differed in HIV-negative AAs (68.3%
in Walley et al. versus 59.6% in He et al.).
While the number of HIV-positive AAs
was similar in both studies (470), the
number of HIV negatives was much
smaller in Walley et al. (227 versus 814).
This creates—asacknowledgedbyWalley
et al.—a 40% likelihood of missing the
detection of a true difference in suscepti-
bility.Moreover, ourHIV-negativesubjects
are comprised of military personnel and
are therefore representative of the military
HIV-positive subjects we evaluated. By
contrast, the characteristics, representa-
tiveness, and sampling methods for the
HIV-negative group are not addressed in
Walley et al. The 471HIV-positive AA sero-
converters evaluated byWalley et al. were
a subset of the seroconverting AAs from
the overall military cohort (Silverberg et al.,
2006), and in these subjects they analyzed
surrogate marker-driven endpoints of
AIDS by 1993 criteria (largely, arrival at
<200CD4+ cells/mm3), rate ofCD4decline,
and VL setpoint.We did not subselect HIV-
positive AAs, and we examined mainly the
clinical endpoint of survival.
Because the US military participates in
a mandatory drug-screening program,
HIV infections are predominantly sexually
acquired. Winkler et al. examined HIV-
negative and HIV-positive (mostly sero-
prevalent) injection drug users of the
ALIVE cohort. However, previous studies
that included this cohort demonstrated
that host genotypes may differentially
influence HIV acquisition, depending on
the route of infection (Martin et al., 2004).
Additionally, analysis of specific loci (e.g.,
SDF1-30A allele) underscore that differ-
ences in route of infection and/or cohort
characteristics may also result in diver-
gent associations forHIVdiseaseprogres-
sion (Daar et al., 2005;Winkler et al., 1998).
Horne et al. studied a smaller sample
size of 295 mostly seroprevalent AAs
selected from the >5000 subjects of the2009 Elsevier Inc.MACS cohort. Among the HIV-positive
AAs studied, 59% were 46C/C, which
differs from the prevalence found in
HIV-positive AAs by the other two groups
or reported by us (67%–71%). Their
controls were from undescribed blood
donors in which 46C/C prevalence
was 68%.
Julg et al. investigated 381 subjects
comprising an untreated subset of a larger
seroprevalent cohort. This may preferen-
tially result in enrollment of slow versus
rapid disease progressors, as the latter
would more likely be placed on therapy,
rendering them ineligible for study partic-
ipation. Also, the evaluation of surrogate
markers of CD4 and VL, rather than
clinical endpoints, and the short duration
of follow up (2003–2006) make direct
comparison of these results with our
longitudinal 15 year follow-up study diffi-
cult.
Although the contrasting results may
reflect differences in study design and
cohorts, they also underscore the
complexity of DARC genotype-pheno-
type relationships and DARC functions
relevant to HIV/AIDS. On average,
subjects of African ancestry have lower
white blood cell (WBC) counts than those
of European descent. In accord with prior
findings (Mayr et al., 2008; Reich et al.,
2009) and those of Julg et al., we also
found that DARC 46C/C is associated
with a low WBC count, and specifically,
low neutrophil and monocyte counts
(data not shown). However, we found
that an intricate interaction between
DARC 46C/C and these hematological
parameters influenced HIV-AIDS suscep-
tibility (Kulkarni et al., 2009) (data not
shown). Thus, akin to the proposal that
over and above its strong link to African
ancestry, DARC 46C/C is associated
with a phenotypic impact on hematologic
parameters (Reich et al., 2009), we
suggest that this genotype associates
with variable HIV/AIDS susceptibility.
This plausibility is further highlighted
by the functional link between DARC
46C/C and variable chemokine levels,
immune/coagulation responses to endo-
toxin, and HIV binding to red blood cells
(He et al., 2008; Mayr et al., 2009; Mayr
et al., 2008). Continued investigation and
vigorous discussion are expected to
lead to enhanced insights regarding the
influence of DARC on HIV acquisition
and disease progression.
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